Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers

Published:2016-03-28 Issue:4 Volume:5 Page:306-313
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Erpenbeck Veit J.¹,Vets Eva²,Gheyle Lien²,Osuntokun Wande³,Larbig Michael¹,Neelakantham Srikanth⁴,Sandham David⁵,Dubois Gerald³,Elbast Walid¹,Goldsmith Paul³,Weiss Markus¹

Affiliation:

1. Novartis Pharma AG Basel Switzerland

2. SGS‐Life Sciences Antwerp Belgium

3. Novartis Institutes for Biomedical Research Horsham United Kingdom

4. Novartis Healthcare Private Limited Hyderabad India

5. Novartis Institutes for Biomedical Research Cambridge, MA USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.244

Reference24 articles.

1. Prostaglandin D2 generation after activation of rat and human mast cells with anti‐IgE;Lewis RA;J Immunol,1982

2. Release of Prostaglandin D2into Human Airways during Acute Antigen Challenge

3. Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy

4. The roles of prostaglandin D2 receptors DP1 and CRTh2 in promoting allergic responses;Pettipher R.;Br J Pharmacol,2008

5. Emerging roles of DP and CRTH2 in allergic inflammation

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The randomized, single‐ and multiple‐ ascending dose studies of the safety, tolerability, pharmacokinetics of CSPCHA115 in healthy Chinese subjects;Clinical and Translational Science;2022-12-09

2. Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial;Journal of Pharmacokinetics and Pharmacodynamics;2022-08-30

3. Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2 receptor antagonist: report of the first-in-human single- and multiple-dose escalation trials in healthy Chinese subjects;Expert Opinion on Investigational Drugs;2022-05-18

4. Role of prostaglandin D2 receptors in the pathogenesis of abdominal aortic aneurysm formation;Clinical Science;2022-03

5. New Treatments for Asthma;Immunology and Allergy Clinics of North America;2021-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3